Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FHIT | P49789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154260 | 0.82 | FHIT (0.35) | FHITALDH1A1MAPTGAAHPGD | |
| SCHEMBL12884245 | 0.80 | ACHE (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL9368305 | 0.67 | ACHE (0.31) | ALDH1A1 | |
| SCHEMBL17340102 | 0.65 | — | — | |
| SCHEMBL24840942 | 0.62 | CA2 (0.34) | — | |
| SCHEMBL10721381 | 0.59 | — | — | |
| SCHEMBL7627662 | 0.59 | ACHE (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL17339878 | 0.59 | — | — | |
| SCHEMBL6384362 | 0.57 | ACHE (0.32) | — | |
| SCHEMBL22927084 | 0.57 | ACHE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | FHIT 4699/4885ALDH1A1 2872/4885MAPT 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.